| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4761095 | Pathology | 2012 | 5 Pages |
Abstract
MGMT methylation appears to be a late event in the biological history of melanoma and is more frequently seen in visceral metastases. The MGMT gene promoter methylation in metastatic disease is associated with longer survival, irrespective of therapy. Thus it could be considered a prognostic factor in metastatic melanoma.
Related Topics
Health Sciences
Medicine and Dentistry
Forensic Medicine
Authors
A.M. Cesinaro, G. Sartori, M. Migaldi, L. Schirosi, G. Pellacani, G. Collina, A. Maiorana,